Ra Pharma (RARX) PT Raised to $34 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street falls as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Ra Pharma (RARX) PT Lowered to $18 at RBC Capital, 'RA101495 ph2 PNH update narrows market but looks viable'
December 5, 2017 10:17 AM ESTRBC Capital lowered its price target on Ra Pharma (NASDAQ: RARX) to $18.00 (from $21.00) while maintaining a Outperform rating.
Analyst Kennen MacKay lowers his PT as the market appears narrower but retains his Outperform recommendation as the drug appears viable. The analyst... More
Ra Pharmaceuticals (RARX) Reports Positive Interim Results from Phase 2 Study of RA101495 SC in PNH
December 4, 2017 7:02 AM ESTRa Pharmaceuticals, Inc. (NASDAQ: RARX) today announced positive interim results from the Companys ongoing, global Phase 2 clinical program evaluating RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharma is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases and is developing RA101495 as a novel,... More
